Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Idiopathic pulmonary fibrosis for \>3 months \<5 years~* High resolution CT scan of chest consistent with IPF within the previous 12 months~* FVC \> 40% and \< 90% predicted, TLC \>40% \<80%, DLCo \>30% \<90%~* Chronic Cough - cough \>8 weeks~* Age \>50~* Non-child bearing potential~Exclusion Criteria:~* Pregnant or lactating women~* Women of child bearing potential~* Known etiology of lung fibrosis other than IPF~* Significant respiratory toxin exposure~* Collagen Vascular Disease~* Use of narcotic anti-cough agent in last week~* significant peripheral vascular disease or neuropathy~* history of seizures~* poorly controlled diabetes~* allergy to thalidomide

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: Thalidomide, then placebo (Type: EXPERIMENTAL): Participants first received Thalidomide tablet for 12 weeks. After a washout period of two weeks, they then received placebo tablet for 12 weeks.
- Experimental: Placebo, then Thalidomide (Type: EXPERIMENTAL): Participants first received Placebo tablet for 12 weeks. After a washout period of two weeks, they then received Thalidomide tablet for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).